TG Therapeutics, Inc. (TGTX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
TG Therapeutics’s revenue went from $152000 in fiscal 2016 to $616M in fiscal 2025, growth of about 151.7% a year.
Net income in fiscal 2025 was $447M, a net margin of 72.6%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $898M and net income $106M.
Free cash flow was -$25M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 229% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $898M | $616M | $329M | $234M | $3M | $7M | $152000 | $152000 | $152000 | $152000 | $152000 |
| Gross profit | $743M | $516M | $291M | $220M | $3M | $6M | — | — | — | — | — |
| Operating income | $193M | $123M | $42M | $21M | -$218M | -$345M | -$274M | -$169M | -$174M | -$119M | -$79M |
| Net income | $106M | $447M | $23M | $13M | -$224M | -$348M | -$279M | -$173M | -$173M | -$118M | -$78M |
| EPS (diluted) | $0.67 | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | $-1.96 | $-2.30 | $-1.91 | $-1.60 |
| R&D | $236M | $160M | $94M | $76M | $125M | $223M | $166M | $154M | $159M | $103M | $69M |
| Revenue growth | — | +87.3% | +40.8% | +8290.0% | −58.4% | +4300.7% | +0.0% | +0.0% | +0.0% | +0.0% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $86M | -$25M | -$41M | -$31M | -$176M | -$296M | -$215M | -$133M | -$129M | -$94M | -$62M |
| Capital spending | -$693000 | -$214000 | -$45000 | $0 | -$14000 | -$401000 | -$357000 | -$131000 | -$90000 | -$2000 | -$344000 |
| Free cash flow | $86M | -$25M | -$41M | -$31M | -$176M | -$296M | -$215M | -$133M | -$129M | -$94M | -$62M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $200M | $91M | $9M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $88M | $65M | $43M | $38M | $45M | $61M | $80M | $11M | $13M | $16M | $8M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $142M | $311M | $218M | $162M | $315M | $605M | $140M | $69M | $85M | $45M |
| Debt | — | $254M | $254M | $111M | $83M | $79M | $42M | $41M | $67000 | $128000 | $68875 |
| Equity | — | $648M | $222M | $161M | $59M | $237M | $519M | $39M | $24M | $67M | $36M |
| Total assets | — | $1.1B | $578M | $330M | $194M | $380M | $626M | $163M | $84M | $97M | $55M |
| Shares (diluted) | 156M | 161M | 160M | 149M | 135M | 132M | 115M | 88M | 75M | 62M | 49M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 82.7% | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | — | — | — | — | — |
| Operating margin | 21.5% | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | -180000.0% | -111200.0% | -114700.0% | -78100.0% | -51953.3% |
| Net margin | 11.8% | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183800.0% | -113700.0% | -114100.0% | -77944.7% | -51482.2% |
| FCF margin | 9.5% | -4.0% | -12.3% | -13.4% | -6326.2% | -4425.7% | -141400.0% | -87458.6% | -84878.3% | -61685.5% | -40744.1% |
| ROIC | — | 10.8% | 8.1% | 7.4% | -154.1% | -109.0% | -48.7% | -212.9% | -723.6% | -176.9% | -219.7% |
| ROE | — | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% | -53.8% | -447.7% | -721.8% | -176.8% | -218.2% |
Frequently asked questions
What is TG Therapeutics’s annual revenue?
$616M in fiscal 2025 and $898M over the twelve months to September 30, 2026.
How much profit does TG Therapeutics make?
Net income was $447M in fiscal 2025 (net margin 72.6%).
Is TG Therapeutics’s revenue growing?
Yes: revenue rose 87.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.